Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Globus Medical

(

GMED

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Globus Medical as such a stock due to the following factors:

  • GMED has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.5 million.
  • GMED has traded 4,175 shares today.
  • GMED is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GMED with the Ticky from Trade-Ideas. See the FREE profile for GMED NOW at Trade-Ideas

More details on GMED:

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. It offers products that address an array of spinal pathologies, anatomies, and surgical approaches. GMED has a PE ratio of 28. Currently there are 11 analysts that rate Globus Medical a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Globus Medical has been 440,100 shares per day over the past 30 days. Globus Medical has a market cap of $1.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.07 and a short float of 11.1% with 16.83 days to cover. Shares are up 14.3% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Globus Medical as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • The stock has not only risen over the past year, it has done so at a faster pace than the S&P 500, reflecting the earnings growth and other positive factors similar to those we have cited here. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • GLOBUS MEDICAL INC has improved earnings per share by 18.2% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, GLOBUS MEDICAL INC increased its bottom line by earning $0.97 versus $0.73 in the prior year. This year, the market expects an improvement in earnings ($1.02 versus $0.97).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 16.6% when compared to the same quarter one year prior, going from $21.14 million to $24.65 million.
  • GMED's revenue growth trails the industry average of 26.3%. Since the same quarter one year prior, revenues rose by 15.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • GMED has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.33, which clearly demonstrates the ability to cover short-term cash needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.